Theriva Biologics, Inc. (TOVX)

USD 1.17

(-1.68%)

Market Cap (In USD)

3.25 Million

Revenue (In USD)

-

Net Income (In USD)

-18.34 Million

Avg. Volume

624.37 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.14-17.0
PE
-
EPS
-
Beta Value
1.338
ISIN
US87164U4094
CUSIP
-
CIK
894158
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Steven A. Shallcross CPA
Employee Count
-
Website
https://therivabio.com
Ipo Date
2006-12-18
Details
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

More Stocks